P2RY12 and cancer: These findings suggest that the characteristics of patients with ACS, such as high thrombotic risk, use of more portent P2Y12 inhibitors, and longer DAPT duration, may amplify mortality rates and cardiovascular events in patients with active or prior history of cancer after PCI.